Community Study to Increase Mammogram Screening Among Overdue Women (IMPLEMENT)

September 16, 2026 updated by: National University Hospital, Singapore

A Community-Based Implementation Study of Pragmatic Interventions to Improve Mammography Uptake in Non-Screen Adherent Women

Breast cancer is the most common cancer among women in Singapore, and regular mammogram screening can detect breast cancer early when treatment is more effective. However, many eligible women do not attend regular mammogram screening despite national screening programs and free screening for eligible women enrolled in Healthier SG.

The IMPLEMENT Study is a community-based implementation study that will evaluate whether practical, low-cost behavioural interventions can increase mammogram screening among women who are overdue for screening or have never been screened. The interventions have previously been shown to be effective in randomized controlled trials conducted by the study team.

The study will be conducted in the Health District @ Queenstown (HD@QT). Women living in Happy Village @ Mei Ling will receive one behavioural intervention that has been shown to be effective in a previous randomized trial, while eligible women living in the remainder of HD@QT will receive usual care with no study intervention. Different implementation trials will be conducted for different screening populations, including women who have never undergone mammography, women who are overdue for repeat mammography, and women who are due for their next mammogram.

The primary objective is to determine whether implementing these evidence-based interventions in a real-world community setting increases the proportion of women completing mammography within four months. Results from this study will help determine whether these interventions can be integrated into community health programs to improve breast cancer screening participation in Singapore.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

15000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Singapore, Singapore
        • National University Hospital Singapore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 69 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Singaporean citizen
  • Age 50-69 years
  • Registered patients of NUHS
  • No history of breast cancer
  • Eligible for free mammograms (Signed up with Healthier SG with a primary care provider within the NUHS Primary Care Network)
  • In each individual trial in this proposed series of trials, the participants will either be:

Repeat screeners: Have undergone a mammogram at least once in the past, but not within the past 2 years Never screeners: Have never done mammogram in the past (no records in EPIC) Active screeners: Have undergone a mammogram within the past 20-24 months but have not scheduled their next screening in Health Appointment System (HAS)

Exclusion Criteria:

  • Diagnosis of breast cancer in EPIC
  • Pregnant woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Evidence-based behavioural intervention

Eligible women residing in Happy Village @ Mei Ling will receive the evidence-based behavioural intervention specified for their screening population. The intervention will be implemented in the community to increase mammography completion within four months. In Trial A on defaulted repeats screeners the intervention will be Mailed Reminder (MR) with dedicated hotline scheduling. In Trial 2 on never-screeners the intervention will be MR with Prescheduled Appointment.

Evidence-based behavioural intervention delivered to eligible women in Happy Village @ Mei Ling to encourage mammography screening. The specific intervention, delivery method, frequency, and duration will be defined for each screening population based on the corresponding previous randomized trial. In Trial 1 the intervention will be mailed reminder (MR) with dedicated appointment scheduling hotline. In Trial 2, the intervention will be MR with prescheduled appointment.

No Intervention: Comparator group

Eligible women residing in the remainder of HD@QT will receive usual care without the study-delivered behavioural intervention. Mammography completion will be assessed using the same outcome definition and follow-up period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of eligible women who complete mammography within four months of intervention delivery.
Time Frame: 4 month

This community-based implementation study will evaluate the effectiveness of evidence-based behavioural interventions to increase mammography screening in eligible women residing in the Health District @ Queenstown. Eligible women living in Happy Village @ Mei Ling will receive the intervention assigned to their screening population, while eligible women living in the remainder of the health district will receive usual care. The study will include implementation cohorts of women who have never undergone mammography, women who are overdue for repeat mammography, and women who are due for their next mammogram. The intervention will be delivered in parallel to usual care, and allocation will be non-randomized based on residential location. Mammography completion will be assessed within four months of intervention delivery.

4 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time from mailed reminder to mammography completion
Time Frame: From mailer delivery through 4 months.

Time from intervention mailer delivery to completion of mammography, measured in days.

From mailer delivery through 4 months.
Time to appointment booking
Time Frame: From mailer delivery through 4 months.

Time from intervention mailer delivery to the first mammography appointment booking, measured in days.

From mailer delivery through 4 months.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Factors associated with mammography completion
Time Frame: Baseline participant characteristics; mammography completion assessed within 4 months

Exploratory analysis of the association between age, ethnicity, housing type, prior mammography history, and time since last mammogram, and mammography completion.

Baseline participant characteristics; mammography completion assessed within 4 months
Mammography appointment no-show rate
Time Frame: From first appointment booking through 4 months after mailer delivery.

Proportion of booked mammography appointments not attended, among participants with available appointment attendance data.

From first appointment booking through 4 months after mailer delivery.
Number of participants attending Happy Village outposts
Time Frame: From intervention delivery through 4 months.

Number of participants in the implementation group who attend Happy Village outposts for screening-related support or services.

From intervention delivery through 4 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2028

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

September 16, 2026

First Submitted That Met QC Criteria

September 16, 2026

First Posted (Actual)

September 22, 2026

Study Record Updates

Last Update Posted (Actual)

September 22, 2026

Last Update Submitted That Met QC Criteria

September 16, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe